The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...

The FTC report showed that from 2017 to 2022, the three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds ...

Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

We recently published a list of 10 Companies Reflect Market Decline. In this article, we are going to take a look at where ...

But high medical costs contributed to results that disappointed Wall Street, and the company’s stock fell on the news that it ...

CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...

Investing.com -- Shares of CVS Health Corp (NYSE:CVS), Cigna (NYSE:CI) Group ... said the "Big 3 PBMs" — CVS’s Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx — imposed ...

UnitedHealth Group Incorporated (NYSE ... along with Cigna’s Express Scripts and CVS Caremark Rx, were able to collectively pocket $7.3 billion in added revenue above cost during the five ...